vaccine as well, caused several cases of poliomyelitis but conferred no immunity. More than a decade later, the memory of the fiascoes still inspired widespread concern about the safety of polio vaccines.
These qualms had become tempered by the early 1950s, as scientists made considerable progress toward the creation of a safe vaccine. By the late 1940s, several groups of researchers had independently identified the three distinct types of poliovirus, a microbial distinction that was essential to the development of an effective vaccine.
At Harvard, John Enders, Frederick Robbins, and Thomas Weller developed a method of growing poliovirus in nonneural tissue using a tissue culture of monkey kidneys -a seminal achievement that won them the Nobel Prize in 1954. At the University of Cincinnati, Albert Sabin began work on a live attenuated oral vaccine that he insisted would provide better immunity than a killed-virus vaccine but that would not be ready for widespread use until 1961. Jonas Salk, who relied on older vaccine-production methods involving formalin-killed viral strains, was able to proceed more rapidly. By early 1953, Salk had begun campaigning relentlessly for a national field trial of his vaccine.
For this critical but unglamorous task, the NFIP turned to Salk's former teacher, Thomas Francis, who had introduced Salk to the design of killedvirus vaccines, and his staff of epidemiologists at the University of Michigan School of Public Health. Francis had a sterling reputation as an investigator and was internationally known for his deft direction of complex field trials of influenzavirus vaccines during World War II. He agreed to conduct the polio-vaccine field trials if three inviolable rules were followed: there would have to be two study groups, one given vaccine and another, at least as large as the vaccine group, given placebo; the trial would have to be conducted in a double-blind manner; and the NFIP was not to interfere. The study formally began on April 26, 1954, when Randy Kerr, a six-year-old boy from McLean, Virginia, received the first inoculation.
No detail of the field trial escaped Francis's watchful gaze -from complex issues of experimental design to such mundane matters as the pack- aging of vaccine, the composition of safety instructions for parents, and the selection of the "Polio Pioneers," the 650,000 children who received the vaccine and the 1.18 million who received a placebo. The trial relied for its implementation on some 150,000 volunteers, 15,000 schools, and 44 state departments of health. Francis admirably withstood the strain of conducting an extremely complex, highstakes experiment in public. Thanks to the relentless campaign of the March of Dimes and the fear that polio and polio vaccines inspired, it was critical that Francis's design be free of bias and confounding variables and that there be no ethical lapses in the conduct of the trial. Everything worked out beautifully.
Coincidentally, Francis's announcement was to be made on the 10th anniversary of Franklin Roosevelt's death, the earliest date by which the University of Michigan's carpenters could complete construction of the long platform that would accommodate the battery of television cameras and radio microphones and the hundreds of photographers and journalists who would cover the event. Before a jam-packed audience of scientists and dignitaries, Francis approached the lectern. He began his speech with two simple declarative sentences: "The vaccine works. It is safe, effective, and potent." He then explained that the Salk vaccine was 60 to 70 percent effective in preventing infection with type 1 poliovirus, the most prevalent strain, and at least 90 percent effective against types 2 and 3.
Thrilling as this news was, there was one person in the auditorium who was visibly unhappy with Francis's report: Jonas Salk. As the diminutive virologist took the podium after Francis's speech, an avalanche of applause greeted him. Yet this public show of appreciation on the part of his scientific peers -a group that had never been accused of being overly effusive -was not enough for Salk, who felt compelled to insist that he had created nothing less than the perfect vaccine. Too flustered even to mention the names of the colleagues who had worked with him at Pittsburgh, Salk assailed the accuracy of Francis's findings. The failures encountered in the trial, he declared, were caused by Merthiolate, a mercury-based antiseptic that had been added to the batches of vaccine, against Salk's wishes, at the express orders of the U.S. Laboratory of Biologics Control. With a dramatic flourish, Salk proclaimed that his new and improved (Merthiolate-free) vaccine might well be 100 percent effective.
Salk's comments created a controversy that his critics used to disparage him for the rest of his career. Backstage, a furious Francis was heard scolding his former student. "What the hell did you have to say that for?" Francis railed. "You're in no position to claim 100 percent effectiveness. What's the matter with you?" 4 Salk's failure to recognize the achievements of his coworkers and his injudicious (albeit ultimately correct) claims aside, the rest of the world was eager to lionize him as a bona fide medical hero. As the journalists scrambled out of the auditorium to call their editors, the spotlight of fame permanently shifted from the epidemiologist to the young creator of the polio vaccine. For many days, there wasn't a front page of a newspaper, a television or radio show, or a newsreel that did not shower Jonas Salk with praise and gratitude. For millions of parents and their children around the world, Salk became the avatar of medical progress. Even so, a decade later, Salk admitted, "I was not unscathed by Ann Arbor." 2 I recently went to my medical school's library to peruse Francis's published, but rarely checked out, account of the 1954 field trial. The book is written in clear, elegant prose, and even a casual reader will recognize its author as a model of scientific integrity, ethical treatment of human subjects, and thorough attention to epidemiologic detail. 5 Still, even in the face of this impressive historical document, it takes little imagination to understand why April 12, 1955, turned out to be Jonas Salk's day. After all, he developed the first effective vaccine against polio; his teacher merely undertook the chore of testing its efficacy on a mass scale and then confirmed to the world that Salk had succeeded.
The annals of medical history are replete with such distinctions.
Yet one of the great benefits of reflecting on the past is the opportunity to adjust one's understanding of events and human interactions. The morning after the announcement, the New York Times heralded Francis's vaccine report as a "medical classic." No one has ever refuted this conclusion. History would be well served, as we commemorate this 50th anniversary, if Tommy Francis's contributions were restored to view.
